SCHEMBL21241823

SCHEMBL21241823

CS(=O)(=O)c1ccc(-c2cccc(-c3csc(NC(=O)CNC(=O)c4ccc(N)cc4)n3)c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 2/20 0.52
▸ KDM4E B2RXH2 1/20 0.52
▸ MEN1 O00255 2/20 0.48
▸ ALDH1A1 P00352 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ GAA P10253 1/20 0.48
▸ PHGDH O43175 12/20 0.47
▸ RORC P51449 1/20 0.46
▸ HDAC3 O15379 3/20 0.46
▸ HDAC1 Q13547 3/20 0.46
▸ HDAC2 Q92769 3/20 0.46
▸ HDAC10 Q969S8 3/20 0.46
▸ HDAC8 Q9BY41 3/20 0.46
▸ HDAC6 Q9UBN7 3/20 0.46
▸ HDAC4 P56524 2/20 0.46
▸ HDAC7 Q8WUI4 2/20 0.46
▸ HDAC11 Q96DB2 2/20 0.46
▸ HDAC9 Q9UKV0 2/20 0.46
▸ HDAC5 Q9UQL6 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21241828 0.89 HDAC3 (0.48) RAB9AKDM4EMEN1ALDH1A1KMT2A
SCHEMBL22971678 0.88 HDAC3 (0.49) RAB9AMEN1KMT2ANPC1HDAC3
SCHEMBL22971635 0.87 ROCK1 (0.56) ALDH1A1HDAC3HDAC1HDAC2HDAC10
SCHEMBL22971660 0.87 HDAC3 (0.46) RAB9AKDM4EMEN1ALDH1A1KMT2A
SCHEMBL22971555 0.86 HDAC3 (0.48) RAB9AMEN1KMT2ANPC1PHGDH
SCHEMBL21241986 0.85 PHGDH (0.51) RAB9AMEN1KMT2ANPC1GAA
SCHEMBL21241936 0.85 HDAC3 (0.50) RAB9AMEN1KMT2ANPC1GAA
SCHEMBL22971654 0.85 ABL1 (0.55) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL22971679 0.85 HDAC3 (0.47) RAB9AMEN1KMT2ANPC1HDAC3
SCHEMBL21225354 0.85 KDM4A (0.59) RAB9AKDM4EMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 — — US disclosed
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 — — US disclosed
US-20210038611-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2021-02-11 — — US disclosed
WO-2019152437-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2019-08-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230138480-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB RAB9A 572/4885KDM4E 1848/4885MEN1 1366/4885
US-20210038611-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB RAB9A 572/4885KDM4E 1848/4885MEN1 1366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback